Personalized and Precision Medicine Journal
Where Innovations Meets Personalized and Precision Medicine

Cancer Immunotherapy Using Microfluidic Systems

Document Type : Review Article

Authors

Maryam Diansaei 1
Parisa Sanati 2

1 Department of veterinary medicine, Islamic Azad University of Tabriz, Tabriz,Iran.

2 Burn and Wound Healing Research Center, Shiraz University of Medical Sciences, 1978-71345, Shiraz, Iran

https://doi.org/10.22034/pmj.2024.713763
Abstract
Physicians are enthusiastic about using a novel approach known as cancer immunotherapy to address various forms of cancer. However, there are occasions when novel therapies that demonstrate efficacy in laboratory settings may not provide the same level of effectiveness when applied to actual patients. To address this issue, scientists are using miniature replicas known as microfluidic models. These models provide the examination of the interaction between cancer and immune cells in a manner that closely resembles the physiological conditions inside the human body. This review examines the role of microfluidic models in advancing the development of more effective cancer therapies. Let's begin by discussing the current state of affairs in cancer immunotherapy. Next, we explore the use of microfluidic models by scientists to gain insights into the mechanisms via which the immune system combats cancer and to evaluate the efficacy of novel therapeutic interventions. Additionally, we discuss the first measures used to demonstrate the efficacy of these models in predicting the effectiveness of therapies in human subjects. Lastly, we will discuss the advantages of using microfluidic models and the necessary steps to enhance their efficacy in the development of novel cancer therapies.
 

Keywords

Microfluidic models
Immunotherapy
Cancer
  1. Mullard A (2021) FDA approves 100th monoclonal antibody product. Nat Rev Drug Discov 20:491–495.
  2. Carter PJ, Lazar GA (2018) Next generation antibody drugs: pursuit of the ‘high-hanging fruit.’ Nat Rev Drug Discov 17:197–223.
  3. Sharma P, Allison JP (2015) The future of immune checkpoint therapy. Science 348:56–61.
  4. Labrijn AF, Janmaat ML, Reichert JM, Parren P (2019) Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov 18:585–608.
  5. Sewnath CA, Behrens LM, van Egmond M (2022) Targeting myeloid cells with bispecific antibodies as novel immunotherapies of cancer. Expert Opin Biol Ther 22:983–995.
  6. June CH, Sadelain M (2018) Chimeric antigen receptor therapy. N Engl J Med 379:64–73.
  7. Olson DJ, Odunsi K (2023) Adoptive cell therapy for nonhematologic solid tumors. J Clin Oncol 41:3397–3407.
  8. Baulu E, Gardet C, Chuvin N, Depil S (2023) TCR-engineered T cell therapy in solid tumors: State of the art and perspectives. Sci Adv 9:eadf3700.
  9. Berrien-Elliott MM, Jacobs MT, Fehniger TA (2023) Allogeneic natural killer cell therapy. Blood 141:856–868.
  10. Constable C, Caplan A (2020) Comparison of the implementation of human papillomavirus and hepatitis B vaccination programs in the United States: Implications for future vaccines. Vaccine 38:954–962.
  11. Rojas LA, Sethna Z, Soares KC et al (2023) Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618:144–150.
  12. Bafaloukos D, Gazouli I, Koutserimpas C, Samonis G (2023) Evolution and Progress of mRNA Vaccines in the Treatment of Melanoma: Future Prospects. Vaccines (Basel).
  13. Shi T, Song X, Wang Y, Liu F, Wei J (2020) Combining oncolytic viruses with cancer immunotherapy: establishing a new generation of cancer treatment. Front Immunol 11:683.
  14. Schlander M, Hernandez-Villafuerte K, Cheng CY, Mestre-Ferrandiz J, Baumann M (2021) How much does it cost to research and develop a new drug? A systematic review and assessment. Pharmacoeconomics 39:1243–1269.
  15. Wouters OJ, McKee M, Luyten J (2020) Estimated research and development investment needed to bring a new medicine to market, 2009–2018. JAMA 323:844–853.
  16. Zuurmond A-M (2019) Fail early, fail fast: a phenotypic rescue approach. Drug Discovery World. https://www.ddw-online.com/fail-early-fail-fast-a-phenotypic-rescue-approach-794-201908. Accessed 13 June 2023
  17. Mestas J, Hughes CC (2004) Of mice and not men: differences between mouse and human immunology. J Immunol 172:2731–2738.
  18. Regmi S, Poudel C, Adhikari R, Luo KQ (2022) Applications of microfluidics and organ-on-a-chip in cancer research. Biosensors (Basel).
  19. Fang Y, Guo Y, Liu T et al (2022) Advances in 3D bioprinting. Chin J Mech Eng Addit Manuf Front 1:100011.
  20. Ko J, Park D, Lee S, Gumuscu B, Jeon NL (2022) Engineering organ-on-a-chip to accelerate translational research. Micromachines (Basel).
  21. Palacio-Castañeda V, Velthuijs N, Le Gac S, Verdurmen WPR (2022) Oxygen control: the often overlooked but essential piece to create better in vitro systems. Lab Chip 22:1068–1092.
  22. Chernyavska M, Schmid M, Freitag PC, Palacio-Castañeda V, Piruska A, Huck WTS, Plückthun A, Verdurmen WPR (2019) Unravelling receptor and RGD motif dependence of retargeted adenoviral vectors using advanced tumor model systems. Sci Rep 9:18568.
  23. Cui X, Ma C, Vasudevaraja V et al (2020) Dissecting the immunosuppressive tumor microenvironments in glioblastoma-on-a-chip for optimized PD-1 immunotherapy. Elife 9:1–21.
  24. Chen W, Ma C, Wang H, Liu L, Tong J, Witkowski M, Aifantis I, Ghassemi S (2023) A bioengineered immunocompetent human leukemia chip for preclinical screening of CAR T cell immunotherapy. Res Sq.
  25. Spijkers XM, Pasteuning-Vuhman S, Dorleijn JC, Vulto P, Wevers NR, Pasterkamp RJ (2021) A directional 3D neurite outgrowth model for studying motor axon biology and disease. Sci Rep 11:2080.
  26. Jiang X, Ren L, Tebon P et al (2021) Cancer-on-a-chip for modeling immune checkpoint inhibitor and tumor interactions. Small 17:e2004282.
  27. Sehgal K, Portell A, Ivanova EV et al (2021) Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade. J Clin Invest.
  28. Preece R, Pavesi A, Gkazi SA et al (2020) CRISPR-mediated base conversion allows discriminatory depletion of endogenous T cell receptors for enhanced synthetic immunity. Mol Ther Methods Clin Dev 19:149–161.
  1. Kerns SJ, Belgur C, Petropolis D et al (2021) Human immunocompetent Organ-on-Chip platforms allow safety profiling of tumor-targeted T-cell bispecific antibodies. Elife. 
  1. Mehrotra A, Leventhal J, Purroy C, Cravedi P (2015) Monitoring T cell alloreactivity. Transpl Rev (Orlando) 29:53–59.
  1. Marzagalli M, Pelizzoni G, Fedi A et al (2022) A multi-organ-on-chip to recapitulate the infiltration and the cytotoxic activity of circulating NK cells in 3D matrix-based tumor model. Front Bioeng Biotechnol 10:945149.
  1. Nguyen OTP, Misun PM, Lohasz C, Lee J, Wang W, Schroeder T, Hierlemann A (2021) An immunocompetent microphysiological system to simultaneously investigate effects of anti-tumor natural killer cells on tumor and cardiac microtissues. Front Immunol 12:781337.  
  1. Gopal S, Kwon SJ, Ku B, Lee DW, Kim J, Dordick JS (2021) 3D tumor spheroid microarray for high-throughput, high-content natural killer cell-mediated cytotoxicity. Commun Biol 4:893.
  1. Ayuso JM, Truttschel R, Gong MM et al (2019) Evaluating natural killer cell cytotoxicity against solid tumors using a microfluidic model. Oncoimmunology 8:1553477. 
  1. Ao Z, Cai H, Wu Z et al (2022) Evaluation of cancer immunotherapy using mini-tumor chips. Theranostics 12:3628–3636. 
  1. Chernyavska M, Hermans CKJC, Chan C, Baumann N, Rösner T, Leusen JHW, Valerius T, Verdurmen WPR (2022) Evaluation of immunotherapies improving macrophage anti-tumor response using a microfluidic model. Organs-on-a-Chip 4:100019.
  1. Aboulkheyr Es H, Zhand S, Thiery JP, Warkiani ME (2020) Pirfenidone reduces immune-suppressive capacity of cancer-associated fibroblasts through targeting CCL17 and TNF-beta. Integr Biol (Camb) 12:188–197. 
  1. Mencattini A, Lansche C, Veith I et al (2022) Direct imaging and automatic analysis in tumor-on-chip reveal cooperative antitumoral activity of immune cells and oncolytic vaccinia virus. Biosens Bioelectron 215:114571.
  1. Kim JH, Lee S, Kang SJ, Choi YW, Choi SY, Park JY, Chang IH (2021) Establishment of three-dimensional bioprinted bladder cancer-on-a-chip with a microfluidic system using Bacillus Calmette-Guerin. Int J Mol Sci.
  1. Hong S, You JY, Paek K et al (2021) Inhibition of tumor progression and M2 microglial polarization by extracellular vesicle-mediated microRNA-124 in a 3D microfluidic glioblastoma microenvironment. Theranostics 11:9687–9704.
  1. CRI Anna-Maria Kellen Clinical Accelerator team (2023) PD-1 / PD-L1 Landscape. Cancer Research Institute. https://www.cancerresearch.org/pd-1-pd-l1-landscapeAccessed 13 June 2023
  2. Picollet-D’hahan N, Zuchowska A, Lemeunier I, Le Gac S (2021) Multiorgan-on-a-chip: a systemic approach to model and decipher inter-organ communication. Trends Biotechnol 39:788–810.

 

Personalized and Precision Medicine Journal
Volume 9, Issue 33 - Serial Number 33
Original article
Spring 2024
Pages 1-6

  • Receive Date 12 February 2024
  • Revise Date 13 April 2024
  • Accept Date 28 May 2024

Home

Publication Ethics

Guide for Authors

Submit Manuscript

Contact Us